

PRELIMINARY PROGRAM

Friday, November 8

09:00- 09:05 Welcome

09:05- 10:05 Session 1

Mass spectrometry in the clinical laboratory – What is it about?

The aim of this session is to provide a general overview of the principle of mass spectrometry, the different mass spectrometry instruments and different method principles (direct injection, sample preparation prior to analysis, single and multianalyte analysis). Applications related to these different instruments and methodological approaches relevant to laboratory medicine will be provided.

At the end of this session, participants should be able to:

- Describe the principle of mass spectrometry
- Understand different methodological approaches used to measure analytes in laboratory medicine
- Summarize different areas in laboratory medicine where mass spectrometry is being used

Moderator: Hubert Vesper

- Presentation Title: TBD Speaker: William (Bill) Clark

Presentation Title: TBD Speaker: TBD

10:05-10:20 Break

10:20- 11:50 Session 2

LC-MS/MS in TDM – Addressing new clinical needs fast

The aim of this session is to provide insights in use of mass spectrometry for therapeutic drug monitoring and its advantages over other conventional methodologies. Examples will be provided on how mass spectrometry provides the clinical laboratory with flexibility to effectively address new challenging situations in patient care.

At the end of this session, participants will be able to:


- Describe commonly used applications of mass spectrometry in TDM
- Explain using examples how mass spectrometry can address clinical needs
- Discuss different applications used in TDM



Under the Auspices of

111111111111111





Moderator: TBD

Presentation Title: Overview of mass spectrometry in TDM Speaker: TBD

Presentation Title: Measurement of CFTR modulators in Cystic Fibrosis Speaker: Katharina Habler

Presentation Title: TDM of immunosuppressive drugs in organ transplant patients by LC-MS/MS **Speaker: TBD**

12:00- 13:15 Session 3

LC-MS/MS applications in Endocrinology – Improving the diagnosis and treatment of endocrine diseases

The aim of this session is to describe current challenges in endocrine testing and approaches to overcome them by use of mass spectrometry.

At the end of this session, participants will be able to:

- Summarize the analytical performance of traditional technologies measuring hormones and other endocrine biomarkers
- Explain how mass spectrometry can address current limitations with endocrine testing
- List examples of established applications for endocrine analytes

Moderator: Uta Ceglarek

Presentation Title: Assessing adrenal and gonadal disorders in men and women using mass spectrometry

Speaker: Wiebke Arlt

Presentation Title: Mass spectrometry in pediatric endocrinology a physician's perspective **Speaker: Prof. Wölfle**


Presentation Title: Enhancing primary Newborn Screening for Congenital Adrenal Hyperplasia with LC-MS3 methodology **Speaker: Alexander Gaudi**



Under the Auspices of

1111000000000000000000





13:15-14:00 Light Lunch

14:00-15:30 Manufacturer Round Tables

15:30- 16:45 Session 4 Ensuring the quality of measurements for mass spectrometry assays – is there anything special?

This session provides an overview on how mass spectrometry assays can be integrated in the existing laboratory infrastructure and on tools available to the laboratory to ensure quality and consistency of patient results. It provides information about experiences with operating LDTs and fully automated systems.

At the end of this session, participants will be able to:

- Describe parameters unique to mass spectrometry methods that need to be controlled to ensure appropriate quality
- Understand approaches to integrate mass spectrometry methods in the laboratory quality system
- List tools available to laboratories to ensure quality and reliability of measurements

Moderator: Alexander Haliassos, Serafeim Karathanos

Quality systems for commercial and lab developed mass spec tests – Is there a difference? **Speaker: Michael Vogeser**


Guidelines for implementation and use of mass spectrometry in laboratory medicine **Speaker: TBD**

From EQA to formal standardization programs – QA Tools and services available to laboratories **Speaker: Hubert Vesper**

17:00-18:00 Manufacturer Round Tables

Social Event





Saturday, November 9

09:00- 09:05 Welcome

09:05-10:15 Session 5

Mass spectrometry as a new tool in the laboratory portfolio – **Is it value for money?** *In this interactive session the advantages, challenges and opportunities of clinical LC-MS/MS as alternate to,*

or as addition to, traditional clinical analyzer-based assays will be discussed. Brief presentations describing the viewpoints from different stakeholders will provided and then discussed with the audience.

At the end of this session, participants will be able to:

- Explain how mass spectrometry can complement current testing options in the laboratory
- Understand limitations of mass spectrometry and administrative challenges in implementing this technology in clinical laboratories
- Describe the impact mass spectrometry can have to patient care

Moderator: Kostas Makris/ Hubert Vesper

The laboratory viewpoint **Speaker: Uta Ceglarek**


The IVD-industry viewpoint **Speaker: Judith Taibon**

The Physician's viewpoint Speaker: TBA

The IFCC SD viewpoint Speaker: Christa Cobbaert

10:15- 10:30 Break





10:30-11:45 Session 6

Clinical mass spectrometry - beyond small molecules: Quo Vadis?

This session provides an outlook of new and emerging applications of mass spectrometry in laboratory medicine and insights into challenges of transferring research methods into clinical practice.

At the end of this session, participants will be able to:

- Describe new research methods in lipidomics and challenges to implement them in the clinical laboratory

- Understand approaches used to analyze large, complex proteins by mass spectrometry
- Explain how measurements of multiple analytes can assist with precision medicine

Moderator: Christa Cobbaert


Lipidomics biomarker discovery – the Ceramide Case study Speaker: TBD

Development of a Reference Measurement Procedure for cTnl standardization **Speaker: Claudia Swart**

Demonstrating Clinical Performance and Clinical Effectiveness of a 7-plex serum Apolipoprotein Panel in the Odyssey Outcomes Trial. Speaker: Christa Cobbaert

11:45-12:00 IFCC Symposium Closing Remarks





22nd National Congress of the Greek Society of Clinical Chemistry- Clinical Biochemistry

12:00-13:00 Oral Presentations

13:00-13:45 Lecture on Mass Spectrometry

Clinical proteomics in the era of precision medicine **Speaker: Michalis Aivaliotis**

13:45-14:30 Sponsored Satellite Symposium

14.30-15.30 Light Lunch Break

15:30-16:30 Symposium on Mass Spectrometry

Moderator: TBA Endocrine testing using Mass Spectrometry Speaker: Anemieke C. Heijboer

Identification of biomarkers using Mass Spectrometry-based metabolomics analysis **Speaker: George Theodoridis**


Newborn screening using Mass Spectrometry Speaker: Giovanny Rodríguez-Blanco

17:00 -18:00 Guest Lecture

The future of standalone HPLC as an analytical technique in the Clinical Laboratory

19:00 Welcome





Sunday November 10th

09.00-10.00 Oral presentations

10.00-11.00 Symposium on Mass Spectrometry

The role of Mass Spectrometry in the measurement of vitamins and their metabolites (focus on vitamin D metabolites)

Speaker: Markus Herrmann

Human sports drug testing (monitoring doping) by mass spectrometry TBA

Services provided by a Metrology Laboratory relevant to Laboratory Medicine (title not final) Speaker: Elias Kakoulidis

11.00-11.30 Coffee Break

11.30-12.30 Symposium on Mass Spectrometry applications

Steroid hormone analysis of adolescents and young women with polycystic ovarian syndrome and adrenocortical dysfunction using UPC2-MS/MS. Speaker: Konstantinos Stratakis

Untargeted proteomics for identification of biomarkers Speaker: Martina Samiotaki

Metabolomic and molecular insights into sickle cell disease and innovative therapies **Speaker: TBA**


Mass spectrometry for the identification of biomarkers for Coronary Artery disease **Speaker: Paolo Magni**





111111111111111





12:30-13:30 Sponsored Satellite Symposium

13:30-14:30 Light Lunch Break

14:30-15:30 Cardiovascular Disease biomarkers Hypertriglyceridemia, what do we do in clinical practice? Speaker: Kalliopi Grigoriou

Lp(a), structure and metabolism Speaker: Adamantia Kalyva

Lp(a), laboratory analysis, reliability of measurement methods, interferences, errors, new methods.

Speaker: Georgia Konisti

Pathophysiological mechanisms, association of Lp(a) with aortic stenosis and cardiovascular events.


Speaker: Charalambos Papastamos

Lp(a) and cardiovascular disease, evidence from clinical studies. Speaker: Spyridon Simantiris

Management of the patient with elevated Lp(a), current management and newer therapeutic horizons

Speaker: Ioannis Andrikou





15:30-16:30 EQA in clinical laboratories

The Utility of Horizontal Guidelines for the Assessment of Clinical Laboratories **Speaker: Panagiotis Kanellopoulos**

Artificial intelligence in External Quality Assessment - Proficiency Testing schemes (EQA-PT) in Laboratory Medicine **Speaker: Alexander Haliassos**

18:00 CLOSING REMARKS

